Show simple item record

dc.contributor.advisorHutt, Peter Bartonen_US
dc.contributor.authorOsvald-Mruz, Christine A.en_US
dc.date.accessioned2012-12-07T20:11:06Z
dc.date.issued1994en_US
dc.identifier.citationPBM and Pharmaceutical Company Mergers: Policy and Regulatory Implications (1994 Third Year Paper)en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10018984
dc.description.abstractA recent trend in the pharmaceutical industry has been for large pharmaceutical companies to acquire or merge with PBMs (prescriptionlpharmacy-benefits-management companies). Merck started this trend in November 1993 by merging with a PBM named Medco; two other pharmaceutical giants have followed suit. Since such mergers are a recent phenomenon, their full-scale implications are as yet unknown and there is little regulation in place specifically to address their potential effects. This essay describes the current state of affairs of PBM-pharmaceutical company alliances and explores their implications for the pharmaceutical and health care industries and the players involved. It further discusses the regulatory bodies involved, the measures they have taken to date, and possible future courses of action.en
dc.language.isoen_USen
dash.licenseLAAen_US
dc.subjectFood and Drug Lawen
dc.subjectmergersen
dc.subjectdrug companiesen
dc.titlePBM and Pharmaceutical Company Mergers: Policy and Regulatory Implicationsen
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-12-07T20:11:06Z
dash.authorsorderedfalse


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record